SINT
Sintx Technologies, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.40
P/S
6.89
EV/EBITDA
-0.63
DCF Value
$-8.17
FCF Yield
-124.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-19.7%
Operating Margin
-1053.1%
Net Margin
-1678.1%
ROE
-400.1%
ROA
-179.7%
ROIC
-173.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $341.0K | $-2.2M | $-0.50 |
| FY 2025 | $1.0M | $-17.1M | $-6.16 |
| Q3 2025 | $208.0K | $-10.3M | $-3.46 |
| Q2 2025 | $100.0K | $-2.3M | $-0.91 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.66
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.